Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. (PPBT) generates frequent news as a clinical-stage oncology company developing therapies that, according to its own reports, target tumor immune evasion and drug resistance. Investors and observers following PPBT news can track updates on its CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219, as well as financing and listing developments.
Recent press releases highlight CAPTN-3 as a key source of news. The company has announced manufacturing milestones for IM1240, the first tri-specific antibody from the platform targeting 5T4, CD3 and NKG2A, including achievement of a commercially viable yield. Additional updates describe non-human primate toxicology data for IM1240, with Purple Biotech reporting an expanded therapeutic window compared with a non-capped comparator and a pharmacokinetic profile characterized by increased systemic exposure and prolonged half-life in that study.
News flow also covers preclinical data presentations at scientific meetings such as the ESMO Immuno-Oncology Congress and other conferences. These releases describe anti-tumor activity of IM1240 and IM1305 in models resistant to prior PD-1 therapy, transcriptomic analyses supporting the inclusion of an NKG2A arm, and ex vivo results in patient-derived tumor biopsies. Such items provide context on how the company positions CAPTN-3 within immuno-oncology research.
Beyond CAPTN-3, Purple Biotech issues updates on CM24 Phase 2 data in pancreatic ductal adenocarcinoma and on NT219, including an intention to grant a European patent for NT219 combination regimens and progress of a Phase 2 study in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Financial and corporate news includes quarterly results, public offerings of American Depositary Shares and warrants, at-the-market offering agreements, and Nasdaq minimum bid price notifications.
Readers who monitor PPBT news can use this page to follow scientific milestones, regulatory and clinical progress, capital-raising transactions, and listing-related announcements directly sourced from company press releases and SEC-furnished documents.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.